nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—CYP19A1—esophageal cancer	0.576	1	CbGaD
Raloxifene—AOX1—Methotrexate—esophageal cancer	0.145	0.772	CbGbCtD
Raloxifene—CYP2B6—Cisplatin—esophageal cancer	0.0429	0.228	CbGbCtD
Raloxifene—Coronary heart disease—Cisplatin—esophageal cancer	0.0152	0.167	CcSEcCtD
Raloxifene—Retinal vein thrombosis—Methotrexate—esophageal cancer	0.00572	0.0629	CcSEcCtD
Raloxifene—Flavoxate—PDE4D—esophageal cancer	0.00362	1	CrCbGaD
Raloxifene—Thromboembolic event—Capecitabine—esophageal cancer	0.00299	0.0329	CcSEcCtD
Raloxifene—Coronary artery disease—Cisplatin—esophageal cancer	0.00277	0.0304	CcSEcCtD
Raloxifene—Thromboembolic event—Methotrexate—esophageal cancer	0.00223	0.0245	CcSEcCtD
Raloxifene—Varicose vein—Capecitabine—esophageal cancer	0.00216	0.0238	CcSEcCtD
Raloxifene—ESR2—neck—esophageal cancer	0.00161	0.0756	CbGeAlD
Raloxifene—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00132	0.0146	CcSEcCtD
Raloxifene—Infection—Carboplatin—esophageal cancer	0.00132	0.0145	CcSEcCtD
Raloxifene—Embolism—Capecitabine—esophageal cancer	0.00126	0.0138	CcSEcCtD
Raloxifene—Tenderness—Cisplatin—esophageal cancer	0.00125	0.0138	CcSEcCtD
Raloxifene—Neuralgia—Capecitabine—esophageal cancer	0.00116	0.0127	CcSEcCtD
Raloxifene—Pain—Carboplatin—esophageal cancer	0.00114	0.0125	CcSEcCtD
Raloxifene—Laryngitis—Capecitabine—esophageal cancer	0.00112	0.0123	CcSEcCtD
Raloxifene—ESR1—neck—esophageal cancer	0.00111	0.0517	CbGeAlD
Raloxifene—ESR2—epithelium—esophageal cancer	0.0011	0.0514	CbGeAlD
Raloxifene—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.00109	0.012	CcSEcCtD
Raloxifene—ESR2—smooth muscle tissue—esophageal cancer	0.00106	0.0495	CbGeAlD
Raloxifene—Body temperature increased—Carboplatin—esophageal cancer	0.00105	0.0116	CcSEcCtD
Raloxifene—AOX1—bronchus—esophageal cancer	0.00104	0.0487	CbGeAlD
Raloxifene—Vaginal discharge—Methotrexate—esophageal cancer	0.000986	0.0108	CcSEcCtD
Raloxifene—Deep vein thrombosis—Methotrexate—esophageal cancer	0.000986	0.0108	CcSEcCtD
Raloxifene—AOX1—trachea—esophageal cancer	0.000935	0.0438	CbGeAlD
Raloxifene—Embolism—Methotrexate—esophageal cancer	0.000934	0.0103	CcSEcCtD
Raloxifene—SIGMAR1—bronchus—esophageal cancer	0.000838	0.0392	CbGeAlD
Raloxifene—ESR2—digestive system—esophageal cancer	0.000835	0.0391	CbGeAlD
Raloxifene—SIGMAR1—smooth muscle tissue—esophageal cancer	0.00082	0.0384	CbGeAlD
Raloxifene—HTR2B—smooth muscle tissue—esophageal cancer	0.000818	0.0383	CbGeAlD
Raloxifene—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00081	0.0089	CcSEcCtD
Raloxifene—Pulmonary embolism—Capecitabine—esophageal cancer	0.000806	0.00886	CcSEcCtD
Raloxifene—Blood pressure increased—Capecitabine—esophageal cancer	0.000806	0.00886	CcSEcCtD
Raloxifene—AOX1—digestive system—esophageal cancer	0.000804	0.0376	CbGeAlD
Raloxifene—SIGMAR1—trachea—esophageal cancer	0.000752	0.0352	CbGeAlD
Raloxifene—ESR1—epithelium—esophageal cancer	0.000752	0.0352	CbGeAlD
Raloxifene—ESR1—smooth muscle tissue—esophageal cancer	0.000725	0.0339	CbGeAlD
Raloxifene—Breast disorder—Cisplatin—esophageal cancer	0.000717	0.00788	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000715	0.00785	CcSEcCtD
Raloxifene—ESR2—lung—esophageal cancer	0.000698	0.0327	CbGeAlD
Raloxifene—Diabetes mellitus—Capecitabine—esophageal cancer	0.000673	0.00739	CcSEcCtD
Raloxifene—AOX1—lung—esophageal cancer	0.000672	0.0314	CbGeAlD
Raloxifene—Gastroenteritis—Capecitabine—esophageal cancer	0.00066	0.00725	CcSEcCtD
Raloxifene—HTR2B—digestive system—esophageal cancer	0.000646	0.0302	CbGeAlD
Raloxifene—Hot flush—Capecitabine—esophageal cancer	0.000625	0.00687	CcSEcCtD
Raloxifene—Menopausal symptoms—Capecitabine—esophageal cancer	0.00062	0.00681	CcSEcCtD
Raloxifene—Arthritis—Capecitabine—esophageal cancer	0.000602	0.00662	CcSEcCtD
Raloxifene—Vaginal inflammation—Methotrexate—esophageal cancer	0.0006	0.00659	CcSEcCtD
Raloxifene—Pulmonary embolism—Methotrexate—esophageal cancer	0.0006	0.00659	CcSEcCtD
Raloxifene—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000597	0.00656	CcSEcCtD
Raloxifene—Conjunctivitis—Cisplatin—esophageal cancer	0.000594	0.00653	CcSEcCtD
Raloxifene—Cystitis noninfective—Methotrexate—esophageal cancer	0.000586	0.00644	CcSEcCtD
Raloxifene—Cystitis—Methotrexate—esophageal cancer	0.000579	0.00637	CcSEcCtD
Raloxifene—Migraine—Capecitabine—esophageal cancer	0.000576	0.00633	CcSEcCtD
Raloxifene—ESR1—digestive system—esophageal cancer	0.000572	0.0268	CbGeAlD
Raloxifene—Vaginal infection—Methotrexate—esophageal cancer	0.000566	0.00622	CcSEcCtD
Raloxifene—CYP2B6—bronchus—esophageal cancer	0.000547	0.0256	CbGeAlD
Raloxifene—Bladder pain—Methotrexate—esophageal cancer	0.000542	0.00596	CcSEcCtD
Raloxifene—Urinary tract disorder—Cisplatin—esophageal cancer	0.000542	0.00596	CcSEcCtD
Raloxifene—SIGMAR1—lung—esophageal cancer	0.000541	0.0253	CbGeAlD
Raloxifene—Connective tissue disorder—Cisplatin—esophageal cancer	0.000539	0.00593	CcSEcCtD
Raloxifene—HTR2B—lung—esophageal cancer	0.000539	0.0253	CbGeAlD
Raloxifene—Urethral disorder—Cisplatin—esophageal cancer	0.000538	0.00591	CcSEcCtD
Raloxifene—Breast disorder—Capecitabine—esophageal cancer	0.000529	0.00581	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000527	0.00579	CcSEcCtD
Raloxifene—Cardiac disorder—Cisplatin—esophageal cancer	0.000509	0.0056	CcSEcCtD
Raloxifene—Flushing—Cisplatin—esophageal cancer	0.000509	0.0056	CcSEcCtD
Raloxifene—Influenza—Capecitabine—esophageal cancer	0.000506	0.00556	CcSEcCtD
Raloxifene—Diabetes mellitus—Methotrexate—esophageal cancer	0.000501	0.0055	CcSEcCtD
Raloxifene—Bronchitis—Capecitabine—esophageal cancer	0.000486	0.00534	CcSEcCtD
Raloxifene—ESR1—lung—esophageal cancer	0.000478	0.0224	CbGeAlD
Raloxifene—ESR2—lymph node—esophageal cancer	0.000477	0.0223	CbGeAlD
Raloxifene—Flatulence—Cisplatin—esophageal cancer	0.000471	0.00518	CcSEcCtD
Raloxifene—Weight increased—Capecitabine—esophageal cancer	0.00046	0.00506	CcSEcCtD
Raloxifene—Muscle spasms—Cisplatin—esophageal cancer	0.000459	0.00505	CcSEcCtD
Raloxifene—AOX1—lymph node—esophageal cancer	0.000459	0.0215	CbGeAlD
Raloxifene—Pneumonia—Capecitabine—esophageal cancer	0.000453	0.00498	CcSEcCtD
Raloxifene—Depression—Capecitabine—esophageal cancer	0.000449	0.00494	CcSEcCtD
Raloxifene—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000444	0.00488	CcSEcCtD
Raloxifene—Conjunctivitis—Capecitabine—esophageal cancer	0.000438	0.00482	CcSEcCtD
Raloxifene—Urinary tract infection—Capecitabine—esophageal cancer	0.000438	0.00482	CcSEcCtD
Raloxifene—CYP2B6—digestive system—esophageal cancer	0.000423	0.0198	CbGeAlD
Raloxifene—Myalgia—Cisplatin—esophageal cancer	0.000407	0.00447	CcSEcCtD
Raloxifene—Rhinitis—Capecitabine—esophageal cancer	0.000406	0.00446	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000404	0.00444	CcSEcCtD
Raloxifene—Hypoaesthesia—Capecitabine—esophageal cancer	0.000403	0.00443	CcSEcCtD
Raloxifene—Pharyngitis—Capecitabine—esophageal cancer	0.000402	0.00441	CcSEcCtD
Raloxifene—Urinary tract disorder—Capecitabine—esophageal cancer	0.0004	0.00439	CcSEcCtD
Raloxifene—Oedema peripheral—Capecitabine—esophageal cancer	0.000399	0.00438	CcSEcCtD
Raloxifene—Connective tissue disorder—Capecitabine—esophageal cancer	0.000398	0.00437	CcSEcCtD
Raloxifene—Urethral disorder—Capecitabine—esophageal cancer	0.000397	0.00436	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—esophageal cancer	0.000394	0.00433	CcSEcCtD
Raloxifene—Infection—Cisplatin—esophageal cancer	0.000387	0.00426	CcSEcCtD
Raloxifene—Nervous system disorder—Cisplatin—esophageal cancer	0.000382	0.0042	CcSEcCtD
Raloxifene—Thrombocytopenia—Cisplatin—esophageal cancer	0.000382	0.0042	CcSEcCtD
Raloxifene—Skin disorder—Cisplatin—esophageal cancer	0.000379	0.00416	CcSEcCtD
Raloxifene—Hyperhidrosis—Cisplatin—esophageal cancer	0.000377	0.00414	CcSEcCtD
Raloxifene—CYP19A1—lymph node—esophageal cancer	0.000376	0.0176	CbGeAlD
Raloxifene—Flushing—Capecitabine—esophageal cancer	0.000376	0.00413	CcSEcCtD
Raloxifene—Cardiac disorder—Capecitabine—esophageal cancer	0.000376	0.00413	CcSEcCtD
Raloxifene—SIGMAR1—lymph node—esophageal cancer	0.00037	0.0173	CbGeAlD
Raloxifene—HTR2B—lymph node—esophageal cancer	0.000369	0.0173	CbGeAlD
Raloxifene—Angiopathy—Capecitabine—esophageal cancer	0.000367	0.00404	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000355	0.00391	CcSEcCtD
Raloxifene—CYP2B6—lung—esophageal cancer	0.000353	0.0165	CbGeAlD
Raloxifene—Flatulence—Capecitabine—esophageal cancer	0.000347	0.00382	CcSEcCtD
Raloxifene—Muscle spasms—Capecitabine—esophageal cancer	0.000339	0.00372	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—esophageal cancer	0.000338	0.00371	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000337	0.0037	CcSEcCtD
Raloxifene—Depression—Methotrexate—esophageal cancer	0.000335	0.00368	CcSEcCtD
Raloxifene—Pain—Cisplatin—esophageal cancer	0.000334	0.00367	CcSEcCtD
Raloxifene—ESR1—lymph node—esophageal cancer	0.000327	0.0153	CbGeAlD
Raloxifene—Conjunctivitis—Methotrexate—esophageal cancer	0.000326	0.00359	CcSEcCtD
Raloxifene—Sweating—Methotrexate—esophageal cancer	0.000322	0.00354	CcSEcCtD
Raloxifene—CYP3A4—digestive system—esophageal cancer	0.000319	0.0149	CbGeAlD
Raloxifene—Vertigo—Capecitabine—esophageal cancer	0.000316	0.00348	CcSEcCtD
Raloxifene—Syncope—Capecitabine—esophageal cancer	0.000316	0.00347	CcSEcCtD
Raloxifene—Loss of consciousness—Capecitabine—esophageal cancer	0.00031	0.0034	CcSEcCtD
Raloxifene—Body temperature increased—Cisplatin—esophageal cancer	0.000308	0.00339	CcSEcCtD
Raloxifene—Cough—Capecitabine—esophageal cancer	0.000307	0.00338	CcSEcCtD
Raloxifene—Arthralgia—Capecitabine—esophageal cancer	0.0003	0.0033	CcSEcCtD
Raloxifene—Myalgia—Capecitabine—esophageal cancer	0.0003	0.0033	CcSEcCtD
Raloxifene—Chest pain—Capecitabine—esophageal cancer	0.0003	0.0033	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—esophageal cancer	0.000299	0.00329	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000298	0.00327	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—esophageal cancer	0.000297	0.00327	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—esophageal cancer	0.000295	0.00325	CcSEcCtD
Raloxifene—Infection—Capecitabine—esophageal cancer	0.000286	0.00314	CcSEcCtD
Raloxifene—Shock—Capecitabine—esophageal cancer	0.000283	0.00311	CcSEcCtD
Raloxifene—Nervous system disorder—Capecitabine—esophageal cancer	0.000282	0.0031	CcSEcCtD
Raloxifene—Thrombocytopenia—Capecitabine—esophageal cancer	0.000281	0.00309	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—esophageal cancer	0.00028	0.00307	CcSEcCtD
Raloxifene—Skin disorder—Capecitabine—esophageal cancer	0.000279	0.00307	CcSEcCtD
Raloxifene—Hyperhidrosis—Capecitabine—esophageal cancer	0.000278	0.00305	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—esophageal cancer	0.000273	0.003	CcSEcCtD
Raloxifene—Diarrhoea—Cisplatin—esophageal cancer	0.000267	0.00293	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000262	0.00288	CcSEcCtD
Raloxifene—Insomnia—Capecitabine—esophageal cancer	0.00026	0.00286	CcSEcCtD
Raloxifene—Dyspepsia—Capecitabine—esophageal cancer	0.000253	0.00278	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000248	0.00273	CcSEcCtD
Raloxifene—Vomiting—Cisplatin—esophageal cancer	0.000248	0.00273	CcSEcCtD
Raloxifene—Rash—Cisplatin—esophageal cancer	0.000246	0.0027	CcSEcCtD
Raloxifene—Pain—Capecitabine—esophageal cancer	0.000246	0.0027	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—esophageal cancer	0.000246	0.0027	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—esophageal cancer	0.000236	0.00259	CcSEcCtD
Raloxifene—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000235	0.00258	CcSEcCtD
Raloxifene—Nausea—Cisplatin—esophageal cancer	0.000232	0.00255	CcSEcCtD
Raloxifene—Cough—Methotrexate—esophageal cancer	0.000229	0.00252	CcSEcCtD
Raloxifene—Abdominal pain—Capecitabine—esophageal cancer	0.000227	0.0025	CcSEcCtD
Raloxifene—Body temperature increased—Capecitabine—esophageal cancer	0.000227	0.0025	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—esophageal cancer	0.000223	0.00245	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—esophageal cancer	0.000223	0.00245	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—esophageal cancer	0.000223	0.00245	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000222	0.00244	CcSEcCtD
Raloxifene—Infection—Methotrexate—esophageal cancer	0.000213	0.00234	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—esophageal cancer	0.00021	0.00231	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—esophageal cancer	0.00021	0.0023	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—esophageal cancer	0.000208	0.00228	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—esophageal cancer	0.000207	0.00227	CcSEcCtD
Raloxifene—Diarrhoea—Capecitabine—esophageal cancer	0.000197	0.00216	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000195	0.00214	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—esophageal cancer	0.000194	0.00213	CcSEcCtD
Raloxifene—Dizziness—Capecitabine—esophageal cancer	0.00019	0.00209	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—esophageal cancer	0.000188	0.00207	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000185	0.00203	CcSEcCtD
Raloxifene—Pain—Methotrexate—esophageal cancer	0.000183	0.00201	CcSEcCtD
Raloxifene—Vomiting—Capecitabine—esophageal cancer	0.000183	0.00201	CcSEcCtD
Raloxifene—Rash—Capecitabine—esophageal cancer	0.000181	0.00199	CcSEcCtD
Raloxifene—Dermatitis—Capecitabine—esophageal cancer	0.000181	0.00199	CcSEcCtD
Raloxifene—Headache—Capecitabine—esophageal cancer	0.00018	0.00198	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000175	0.00192	CcSEcCtD
Raloxifene—Nausea—Capecitabine—esophageal cancer	0.000171	0.00188	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—esophageal cancer	0.000169	0.00186	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—esophageal cancer	0.000169	0.00186	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—esophageal cancer	0.000146	0.00161	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—esophageal cancer	0.000142	0.00156	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—esophageal cancer	0.000136	0.0015	CcSEcCtD
Raloxifene—Rash—Methotrexate—esophageal cancer	0.000135	0.00148	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—esophageal cancer	0.000135	0.00148	CcSEcCtD
Raloxifene—Headache—Methotrexate—esophageal cancer	0.000134	0.00147	CcSEcCtD
Raloxifene—Nausea—Methotrexate—esophageal cancer	0.000127	0.0014	CcSEcCtD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	3.4e-05	0.000283	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PDE4D—esophageal cancer	3.4e-05	0.000283	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKAP13—esophageal cancer	3.39e-05	0.000282	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NOTCH1—esophageal cancer	3.38e-05	0.000282	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.35e-05	0.000279	CbGpPWpGaD
Raloxifene—AOX1—Disease—NOS2—esophageal cancer	3.3e-05	0.000275	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GNG7—esophageal cancer	3.28e-05	0.000273	CbGpPWpGaD
Raloxifene—AOX1—Disease—NOTCH1—esophageal cancer	3.27e-05	0.000272	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GNG7—esophageal cancer	3.23e-05	0.000269	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—NOTCH1—esophageal cancer	3.23e-05	0.000269	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PFN1—esophageal cancer	3.22e-05	0.000268	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PLCE1—esophageal cancer	3.2e-05	0.000266	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ADH7—esophageal cancer	3.2e-05	0.000266	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CA1—esophageal cancer	3.18e-05	0.000265	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC10A2—esophageal cancer	3.18e-05	0.000265	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIST1H2BM—esophageal cancer	3.13e-05	0.00026	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.11e-05	0.000259	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PSME2—esophageal cancer	3.11e-05	0.000259	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PSME1—esophageal cancer	3.11e-05	0.000259	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PDE4D—esophageal cancer	3.1e-05	0.000258	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ALDH2—esophageal cancer	3.08e-05	0.000256	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—CREBBP—esophageal cancer	3.07e-05	0.000255	CbGpPWpGaD
Raloxifene—EBP—Metabolism—EP300—esophageal cancer	3.05e-05	0.000254	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—XIAP—esophageal cancer	3.03e-05	0.000252	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.01e-05	0.000251	CbGpPWpGaD
Raloxifene—AOX1—Disease—CREBBP—esophageal cancer	2.96e-05	0.000247	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GNG7—esophageal cancer	2.95e-05	0.000246	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH3—esophageal cancer	2.93e-05	0.000244	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—CREBBP—esophageal cancer	2.93e-05	0.000244	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTT1—esophageal cancer	2.92e-05	0.000243	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CA2—esophageal cancer	2.91e-05	0.000242	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP2A6—esophageal cancer	2.89e-05	0.000241	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ELMO1—esophageal cancer	2.89e-05	0.000241	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.88e-05	0.00024	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNA1—esophageal cancer	2.86e-05	0.000238	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL2—esophageal cancer	2.85e-05	0.000237	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.85e-05	0.000237	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKAP13—esophageal cancer	2.82e-05	0.000235	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ADH1B—esophageal cancer	2.8e-05	0.000233	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—XIAP—esophageal cancer	2.76e-05	0.00023	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ENO1—esophageal cancer	2.74e-05	0.000228	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS1—esophageal cancer	2.74e-05	0.000228	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PLCE1—esophageal cancer	2.71e-05	0.000225	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ADH7—esophageal cancer	2.71e-05	0.000225	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PSME2—esophageal cancer	2.7e-05	0.000225	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PSME1—esophageal cancer	2.7e-05	0.000225	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TYMP—esophageal cancer	2.68e-05	0.000223	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.67e-05	0.000223	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PSME2—esophageal cancer	2.66e-05	0.000221	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PSME1—esophageal cancer	2.66e-05	0.000221	CbGpPWpGaD
Raloxifene—AOX1—Disease—NOS3—esophageal cancer	2.65e-05	0.000221	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ANXA1—esophageal cancer	2.65e-05	0.00022	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH2—esophageal cancer	2.63e-05	0.000219	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNA1—esophageal cancer	2.61e-05	0.000218	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIST1H2BM—esophageal cancer	2.61e-05	0.000217	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP26A1—esophageal cancer	2.61e-05	0.000217	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL2—esophageal cancer	2.6e-05	0.000216	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PDE4D—esophageal cancer	2.58e-05	0.000215	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SST—esophageal cancer	2.57e-05	0.000214	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALOX15—esophageal cancer	2.54e-05	0.000211	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH3—esophageal cancer	2.51e-05	0.000209	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GHRL—esophageal cancer	2.51e-05	0.000209	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CREBBP—esophageal cancer	2.48e-05	0.000206	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB2—esophageal cancer	2.48e-05	0.000206	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FBXW7—esophageal cancer	2.47e-05	0.000205	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GNG7—esophageal cancer	2.46e-05	0.000205	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PSME2—esophageal cancer	2.43e-05	0.000202	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PSME1—esophageal cancer	2.43e-05	0.000202	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—esophageal cancer	2.43e-05	0.000202	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTO1—esophageal cancer	2.42e-05	0.000202	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TPI1—esophageal cancer	2.42e-05	0.000202	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ANXA1—esophageal cancer	2.42e-05	0.000201	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ADH1B—esophageal cancer	2.37e-05	0.000198	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.36e-05	0.000196	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SST—esophageal cancer	2.35e-05	0.000196	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP1B1—esophageal cancer	2.33e-05	0.000194	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALDOB—esophageal cancer	2.32e-05	0.000193	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—XIAP—esophageal cancer	2.3e-05	0.000192	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH3—esophageal cancer	2.29e-05	0.000191	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GHRL—esophageal cancer	2.29e-05	0.000191	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TYMP—esophageal cancer	2.27e-05	0.000189	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PIK3CA—esophageal cancer	2.26e-05	0.000188	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FBXW7—esophageal cancer	2.25e-05	0.000188	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH2—esophageal cancer	2.25e-05	0.000187	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GAPDH—esophageal cancer	2.24e-05	0.000186	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—NOS3—esophageal cancer	2.22e-05	0.000185	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CRABP1—esophageal cancer	2.22e-05	0.000184	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SMAD4—esophageal cancer	2.21e-05	0.000184	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP26A1—esophageal cancer	2.21e-05	0.000184	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNA1—esophageal cancer	2.18e-05	0.000181	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL2—esophageal cancer	2.16e-05	0.00018	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALOX15—esophageal cancer	2.15e-05	0.000179	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN1A—esophageal cancer	2.12e-05	0.000176	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GNG7—esophageal cancer	2.11e-05	0.000175	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH2—esophageal cancer	2.05e-05	0.000171	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TPI1—esophageal cancer	2.05e-05	0.000171	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTO1—esophageal cancer	2.05e-05	0.000171	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—esophageal cancer	2.03e-05	0.000169	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PSME2—esophageal cancer	2.02e-05	0.000168	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PSME1—esophageal cancer	2.02e-05	0.000168	CbGpPWpGaD
Raloxifene—AOX1—Disease—EP300—esophageal cancer	2.02e-05	0.000168	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ANXA1—esophageal cancer	2.01e-05	0.000168	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.01e-05	0.000167	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.01e-05	0.000167	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—HMOX1—esophageal cancer	2e-05	0.000166	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFBR2—esophageal cancer	2e-05	0.000166	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALDH2—esophageal cancer	1.97e-05	0.000164	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.97e-05	0.000164	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.96e-05	0.000163	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SST—esophageal cancer	1.96e-05	0.000163	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ABCB1—esophageal cancer	1.92e-05	0.00016	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GHRL—esophageal cancer	1.91e-05	0.000159	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH3—esophageal cancer	1.91e-05	0.000159	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.89e-05	0.000158	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SMAD4—esophageal cancer	1.89e-05	0.000157	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTT1—esophageal cancer	1.88e-05	0.000156	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FBXW7—esophageal cancer	1.88e-05	0.000156	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.88e-05	0.000156	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP2A6—esophageal cancer	1.86e-05	0.000155	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFBR2—esophageal cancer	1.82e-05	0.000152	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MYC—esophageal cancer	1.82e-05	0.000152	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GNG7—esophageal cancer	1.78e-05	0.000149	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS1—esophageal cancer	1.76e-05	0.000147	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ENO1—esophageal cancer	1.76e-05	0.000147	CbGpPWpGaD
Raloxifene—AOX1—Disease—MYC—esophageal cancer	1.76e-05	0.000146	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MYC—esophageal cancer	1.74e-05	0.000145	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PSME1—esophageal cancer	1.73e-05	0.000144	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PSME2—esophageal cancer	1.73e-05	0.000144	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SMAD4—esophageal cancer	1.72e-05	0.000144	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—esophageal cancer	1.72e-05	0.000143	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH2—esophageal cancer	1.71e-05	0.000142	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.71e-05	0.000142	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA1—esophageal cancer	1.71e-05	0.000142	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—EP300—esophageal cancer	1.69e-05	0.000141	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.67e-05	0.000139	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NOTCH1—esophageal cancer	1.63e-05	0.000136	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.59e-05	0.000132	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.57e-05	0.000131	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.57e-05	0.00013	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA2—esophageal cancer	1.56e-05	0.00013	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HIF1A—esophageal cancer	1.55e-05	0.000129	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFBR2—esophageal cancer	1.52e-05	0.000126	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1B1—esophageal cancer	1.5e-05	0.000125	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—esophageal cancer	1.49e-05	0.000124	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.49e-05	0.000124	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ENO1—esophageal cancer	1.49e-05	0.000124	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KDR—esophageal cancer	1.48e-05	0.000123	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—CREBBP—esophageal cancer	1.48e-05	0.000123	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PSME1—esophageal cancer	1.47e-05	0.000122	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PSME2—esophageal cancer	1.47e-05	0.000122	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.45e-05	0.000121	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADH7—esophageal cancer	1.45e-05	0.000121	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.45e-05	0.000121	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SMAD4—esophageal cancer	1.44e-05	0.00012	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIF1A—esophageal cancer	1.41e-05	0.000117	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP19A1—esophageal cancer	1.41e-05	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	1.39e-05	0.000116	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KDR—esophageal cancer	1.35e-05	0.000112	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.28e-05	0.000107	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CREBBP—esophageal cancer	1.28e-05	0.000107	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.28e-05	0.000107	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.27e-05	0.000106	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH1—esophageal cancer	1.27e-05	0.000106	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.27e-05	0.000105	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CREBBP—esophageal cancer	1.26e-05	0.000105	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—esophageal cancer	1.25e-05	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—esophageal cancer	1.24e-05	0.000103	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.23e-05	0.000103	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TYMP—esophageal cancer	1.22e-05	0.000101	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.19e-05	9.92e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	1.19e-05	9.87e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.18e-05	9.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—esophageal cancer	1.18e-05	9.79e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.15e-05	9.61e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	1.15e-05	9.6e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NOS3—esophageal cancer	1.15e-05	9.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	1.13e-05	9.43e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOS3—esophageal cancer	1.13e-05	9.41e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—esophageal cancer	1.12e-05	9.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.1e-05	9.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TPI1—esophageal cancer	1.1e-05	9.16e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HMOX1—esophageal cancer	1.09e-05	9.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.08e-05	9.01e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	1.08e-05	8.97e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.07e-05	8.88e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH1—esophageal cancer	1.06e-05	8.82e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—esophageal cancer	1.06e-05	8.8e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.06e-05	8.79e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—esophageal cancer	1.05e-05	8.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—esophageal cancer	1.04e-05	8.69e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOS3—esophageal cancer	1.03e-05	8.59e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.02e-05	8.46e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.01e-05	8.38e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	9.83e-06	8.18e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	9.65e-06	8.04e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREBBP—esophageal cancer	9.6e-06	7.99e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNG7—esophageal cancer	9.58e-06	7.97e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—esophageal cancer	9.34e-06	7.78e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	9.04e-06	7.52e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.97e-06	7.47e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—esophageal cancer	8.76e-06	7.3e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—esophageal cancer	8.74e-06	7.27e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—esophageal cancer	8.6e-06	7.16e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOS3—esophageal cancer	8.6e-06	7.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.54e-06	7.11e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—esophageal cancer	8.53e-06	7.1e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.44e-06	7.02e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	8.25e-06	6.87e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CREBBP—esophageal cancer	8.24e-06	6.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—esophageal cancer	8.04e-06	6.69e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO1—esophageal cancer	8e-06	6.66e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS1—esophageal cancer	8e-06	6.66e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.89e-06	6.57e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PSME2—esophageal cancer	7.88e-06	6.56e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PSME1—esophageal cancer	7.88e-06	6.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—esophageal cancer	7.85e-06	6.54e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—esophageal cancer	7.49e-06	6.24e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NOS3—esophageal cancer	7.37e-06	6.14e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—esophageal cancer	7.33e-06	6.1e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—esophageal cancer	7.1e-06	5.91e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.97e-06	5.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—esophageal cancer	6.87e-06	5.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—esophageal cancer	6.84e-06	5.69e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.8e-06	5.66e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—esophageal cancer	6.75e-06	5.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—esophageal cancer	6.69e-06	5.57e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—esophageal cancer	6.54e-06	5.44e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—esophageal cancer	6.46e-06	5.38e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.39e-06	5.32e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	6.36e-06	5.3e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NOS3—esophageal cancer	6.24e-06	5.2e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—esophageal cancer	6.15e-06	5.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.83e-06	4.86e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	5.81e-06	4.83e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—esophageal cancer	5.71e-06	4.75e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—esophageal cancer	5.7e-06	4.74e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—esophageal cancer	5.62e-06	4.68e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—esophageal cancer	5.61e-06	4.67e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.6e-06	4.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—esophageal cancer	5.57e-06	4.64e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—esophageal cancer	4.84e-06	4.03e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—esophageal cancer	4.75e-06	3.95e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—esophageal cancer	4.68e-06	3.9e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—esophageal cancer	4.15e-06	3.45e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.74e-06	3.12e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.51e-06	2.92e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NOS3—esophageal cancer	3.35e-06	2.79e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.07e-06	2.55e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—esophageal cancer	2.55e-06	2.12e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.89e-06	1.57e-05	CbGpPWpGaD
